Tumor News and Research

RSS

Researchers identify miRNA in blood serum of lung cancer patients

Researchers have identified characteristic patterns of molecules called microRNA in the blood of people with lung cancer that might reveal both the presence and aggressiveness of the disease, and perhaps who is at risk of developing it.

13 May 2011

Coffee provides protections from a type of breast cancer: Study

For the study they compared coffee consumption in postmenopausal women with breast cancer and women of the same age without cancer, they found those who drank five or more cups of java a day showed a 0.43 times lower risk of estrogen-receptor negative cancers. Around one in four women diagnosed with breast cancer will have estrogen-receptor negative breast cancer, which is often resilient to drug treatment and requires intensive chemotherapy.

12 May 2011

Researchers help explain why smart drugs are not effective in some cancer patients

Some of the most effective and expensive cancer drugs, dubbed "smart drugs" for their ability to stop tumors by targeting key drivers of cancer cell growth, are not effective in some patients. In two related studies, Yale School of Medicine researchers examined one such driver, the EGF receptor, and found that a decoy receptor might be limiting the amount of drug that gets to the intended target.

12 May 2011

Biocept's paper describes identification of different CTC phenotypes in cancer patients

Biocept, Inc., a privately-held laboratory testing company focused on the detection, enumeration and analysis of circulating tumor cells (CTCs) in cancer patients, today announced the publication of a paper describing the identification of different CTC phenotypes using its proprietary Cell Enrichment and Extraction platform.

12 May 2011

Noninvasive stool test can detect pancreatic cancer

Pancreatic cancer has one of the highest mortality rates of any of the major cancers, and of the 43,000-plus Americans diagnosed with the disease each year, more than 94 percent die within five years of diagnosis. One reason for this high number of deaths is a lack of effective screening tools for catching the disease early.

12 May 2011

Reprogrammed herpes virus can improve early cancer diagnosis

Scientists have used a genetically re-engineered herpes virus that selectively hunts down and infects cancerous tumors and then delivers genetic material that prompts cancers to secrete a biomarker and reveal their presence.

12 May 2011

Neogenix Oncology to receive European Patent for NEO-301 antibody for treatment of pancreatic cancer

Neogenix Oncology is pleased to announce that it will be granted a European Patent relating to its NEO-301 antibody, to take effect beginning September 23, 2011.

12 May 2011

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard, the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies SAS, a diagnostic company specialized in innovative immunomonitoring tests and services, today announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, and a chemotherapeutic agent, XELODA, in the treatment of metastatic breast cancer.

11 May 2011

Common tiny tropical fish plays a key role in new model for Cushing disease

A common, tiny tropical fish plays a key role in a new model for Cushing disease, giving researchers a powerful tool to conduct extensive searches for effective treatments for this serious hormonal disorder, testing up to 300 drugs weekly.

11 May 2011

Inovio first quarter total revenue increases to $3.1 million for 2011

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2011.

11 May 2011

Novel ultrasound-targeted microbubble-destruction technology advances cure for prostate cancer

Cancer researchers are a step closer to finding a cure for advanced prostate cancer after effectively combining an anti-cancer drug with a viral gene therapy in vivo using novel ultrasound-targeted microbubble-destruction (UTMD) technology.

11 May 2011

Plexxikon seeks vemurafenib marketing approval from FDA and EMA for melanoma treatment

Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced that applications for market approval for vemurafenib for the treatment of metastatic melanoma have been submitted to the U.S. Food and Drug Administration and the European Medicines Agency.

11 May 2011

UCLA researchers amp up power of killer CD8 T-cells to fight melanoma

Researchers with UCLA's Jonsson Comprehensive Cancer Center have discovered a way to amp up the power of killer T-cells, called CD8 cells, making them more functional for longer periods of time and boosting their ability to multiply and expand within the body to fight melanoma, a new study has found.

11 May 2011

Micromet first quarter total revenues decrease to $5.5 million

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the first quarter ended March 31, 2011.

10 May 2011

Simcere first quarter total revenue increases 5.1% to RMB482.2 million

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today reported unaudited financial results for the first quarter ended March 31, 2011.

10 May 2011

Bayer's regorafenib granted FDA Fast Track designation for treatment of GIST

Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib (BAY 73-4506) has been granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite at least imatinib and sunitinib as prior treatments.

10 May 2011

Treatment with estrogen-lowering drugs shrinks tumors and reduces mastectomy rates in breast cancer patients

In the first large trial of its kind in the United States, researchers have shown that estrogen-lowering drugs can shrink tumors and reduce mastectomy rates for patients with stage 2 or 3 breast cancer.

10 May 2011

Hitachi to provide Mayo Clinic with two sets of proton beam therapy systems

Hitachi, Ltd. today announced that it has entered into an agreement to provide Mayo Clinic with its proton beam therapy (PBT) system. This next-generation technology has spot scanning capability for treating certain forms of cancer. The agreement includes PBT system maintenance for both facilities for 10 years following completion of the systems' installation.

10 May 2011

CHOP forms first startup firm to develop treatments for peripheral artery disease

Building on its extensive laboratory research using magnetically guided nanoparticles to deliver drugs to diseased blood vessels, The Children's Hospital of Philadelphia has just spun off its first startup company, Vascular Magnetics, Inc.

10 May 2011

Illumina announces price reduction in whole human genome sequencing projects

Illumina, Inc. today announced that it is significantly reducing the price for sequencing whole human genomes through the Illumina Genome Network.

From Illumina, Inc. 9 May 2011

Tumor News and Research

Researchers identify miRNA in blood serum of lung cancer patients

Coffee provides protections from a type of breast cancer: Study

Researchers help explain why smart drugs are not effective in some cancer patients

Biocept's paper describes identification of different CTC phenotypes in cancer patients

Noninvasive stool test can detect pancreatic cancer

Reprogrammed herpes virus can improve early cancer diagnosis

Neogenix Oncology to receive European Patent for NEO-301 antibody for treatment of pancreatic cancer

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Common tiny tropical fish plays a key role in new model for Cushing disease

Inovio first quarter total revenue increases to $3.1 million for 2011

Novel ultrasound-targeted microbubble-destruction technology advances cure for prostate cancer

Plexxikon seeks vemurafenib marketing approval from FDA and EMA for melanoma treatment

UCLA researchers amp up power of killer CD8 T-cells to fight melanoma

Micromet first quarter total revenues decrease to $5.5 million

Simcere first quarter total revenue increases 5.1% to RMB482.2 million

Bayer's regorafenib granted FDA Fast Track designation for treatment of GIST

Treatment with estrogen-lowering drugs shrinks tumors and reduces mastectomy rates in breast cancer patients

Hitachi to provide Mayo Clinic with two sets of proton beam therapy systems

CHOP forms first startup firm to develop treatments for peripheral artery disease

Illumina announces price reduction in whole human genome sequencing projects

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News